Extending the intellectual property of its fully implantable medical device for restoring cardiac output (ICOMS) BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a medical device company developing the FLOWMAKER®, a fully implantable cardiac output restoration system (ICOMS) to address the unmet needs of patients suffering from severe heart failure, announced today that its first […]
Author: Ken Dropiewski
Cardiac Dimensions Receives Medical Device Regulation (MDR) Certification for Carillon Mitral Contour System
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that its Carillon Mitral Contour System® has received certification under Regulation (EU) 2017/745 (“MDR”). The MDR program is intended to ensure high standards […]
Elucid Names Scott Huennekens Executive Chairman of the Board
Proven medtech leader appointed to chair AI-powered cardiovascular technology through commercialization and expansion BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors. “There are few […]
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
WARRINGTON, Pa., April 24, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the closing of its previously announced underwritten public offering of 3,686,006 shares of common stock, and warrants to purchase up […]
GE HealthCare Reports First Quarter 2023 Financial Results
1Q Revenue growth of 8% year-over-year; Organic revenue* growth of 12% 1Q Net income attributable to GE HealthCare of $372 million versus $389 million for the prior year, Adjusted EBIT* of $664 million versus $599 million 1Q Diluted EPS was $0.41 versus $0.86 in the prior year, Adjusted EPS* was […]
Abbott’s Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients
Abbott’s CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott’s CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support […]
Cohere Health Receives 2023 KLAS Points of Light Award
Collaboration honored for streamlining cardiovascular prior authorizations and assisting providers with evidence-based care paths BOSTON, April 25, 2023 /PRNewswire/ — Cohere Health, a recognized leader in transformative prior authorization (PA), has been named a winner of the KLAS 2023 Points of Light award for its collaboration with Humana Inc. and Karing Hearts […]
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 15.78 MILLION IN AN EQUITY PLACEMENT
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 25 April 2023, 06:15 am CEST Ghent, Belgium, 25 April 2023 – Sequana Medical NV (Euronext Brussels: […]
Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients
SEOUL, South Korea, April 25, 2023 /PRNewswire/ — Mezzion Pharma (“Mezzion”), a rare disease focused pharmaceutical company, announced that it has secured nearly $40M USD to fund FUEL-2, their confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion is looking to bring to market JURVIGO® (udenafil), a […]
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating income +18% (cc, +11% USD) IM core margin 38.7%, +360 bps cc, driven by […]



